MedTrace Logo

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

NCT02608619 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2018-08-29

No results posted yet for this study

Summary

The main purpose of this study is to discover how 18F-cholineFCH distributes in the body, and see if it can distinguish active histiocytes (tumor) from inflammatory (non- tumor) cells. This tracer has the potential to give the investigators' team more information when trying to identify the tumor cells that are most important to collect with biopsy. In addition, the study will measure levels of 18F-cholineFCH in the biopsy tissue.

Conditions

  • Erdheim-Chester Disease
  • Langerhans Cell Histiocytosis
  • Histiocytic Disorders

Interventions

RADIATION

F-choline PET Scan

DEVICE

FDG-PET

PROCEDURE

biopsy

Sponsors & Collaborators

Principal Investigators

  • Eli Diamond, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608619 on ClinicalTrials.gov